Literature DB >> 11888896

Expression of p14ARF overcomes tumor resistance to p53.

Wenge Lu1, Jiayuh Lin, Jiandong Chen.   

Abstract

Tumors without p53 mutation are often resistant to p53 gene therapy. We examined the mechanism using p53-resistant A549 cells and p53-sensitive H1299 cells. We found that p53 delivered by adenovirus is poorly expressed in A549 (ARF-null) cells but efficiently expressed in H1299 cells (ARF-positive). Strong p53 expression and apoptosis can be achieved in A549 cells using a p53 mutant resistant to degradation by MDM2 or by coexpression of ARF. The results suggest that enhanced MDM2 activity attributable to loss of ARF contributes to p53 resistance. Surprisingly, tumor cell lines with MDM2 gene amplification are still deficient for ARF expression, suggesting that MDM2 amplification does not substitute for ARF inactivation during tumor development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888896

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Regulation of p53 and MDM2 activity by MTBP.

Authors:  Mark Brady; Nikolina Vlatkovic; Mark T Boyd
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

2.  MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.

Authors:  Chuangui Wang; Alexey Ivanov; Lihong Chen; William J Fredericks; Ed Seto; Frank J Rauscher; Jiandong Chen
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

3.  Regulation of MDMX expression by mitogenic signaling.

Authors:  Daniele M Gilkes; Yu Pan; Domenico Coppola; Timothy Yeatman; Gary W Reuther; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

4.  ETV1 positively regulates transcription of tumor suppressor ARF.

Authors:  Evan Zynda; Mark W Jackson; Partho Bhattacharya; Eugene S Kandel
Journal:  Cancer Biol Ther       Date:  2013-10-23       Impact factor: 4.742

Review 5.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

6.  Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA.

Authors:  Jaesung Kim; Hye Yeong Nam; Tae-Il Kim; Pyung-Hwan Kim; Jihoon Ryu; Chae-Ok Yun; Sung Wan Kim
Journal:  Biomaterials       Date:  2011-04-30       Impact factor: 12.479

7.  MDM2 promotes ubiquitination and degradation of MDMX.

Authors:  Yu Pan; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

8.  Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer.

Authors:  F Andriani; P Perego; N Carenini; G Sozzi; L Roz
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

9.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

10.  Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity.

Authors:  Teng Teng; Carol A Mercer; Philip Hexley; George Thomas; Stefano Fumagalli
Journal:  Mol Cell Biol       Date:  2013-09-23       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.